Last reviewed · How we verify
NCT06355765
Citicoline & Antioxidants in Glaucoma
trial testing Citicoline blackcurrant supplement in Glaucoma, Open-Angle in 60 participants. Completed in 10 December 2022.
10 December 2022
Quick facts
| Lead sponsor | University of Naples |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 10 January 2022 |
| Primary completion | 10 December 2022 |
| Estimated completion | 10 December 2022 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Citicoline blackcurrant supplement
Conditions studied
- Glaucoma, Open-Angle — all drugs for Glaucoma, Open-Angle →
Sponsor
University of Naples
Who can join
Adults 30 to 90, any sex, with Glaucoma, Open-Angle. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the long-term effects of oral citicoline, vitamins A, B, C and E, and blackcurrant therapy in patients with primary open-angle glaucoma (POAG) using optical coherence tomography (OCT), OCT angiography (OCTA) and microperimetry parameters.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Impact of Oral Citicoline, Antioxidant Vitamins, and Blackcurrant Supplementation on Primary Open-Angle Glaucoma: An OCT and OCTA Study.
Giunta P, D'Andrea L, Rinaldi M, Laezza MP, et al · · 2025 · cited 1× · PMID 40564070 · DOI 10.3390/biomedicines13061352
Verify or expand the search:
- PubMed search for NCT06355765
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glaucoma, Open-Angle
Currently open trials in the same condition.
- NCT06964191 — Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension · Phase 2 · recruiting
- NCT06240312 — Optic Nerve Head Strain as Biomarker for Glaucoma · NA · recruiting
- NCT05405868 — Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial · Phase 3 · recruiting
- NCT05710198 — Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma · Phase 3 · recruiting
- NCT06058598 — Exercise Training in Patients With Glaucoma · NA · active not recruiting
Other University of Naples trials
Trials by the same sponsor.
- NCT07305298 — Mirabegron in Patients With Age-Related Macular Degeneration · not yet recruiting
- NCT06629662 — Robotic Versus Laparoscopic Sleeve Gastrectomy · NA · recruiting
- NCT06184906 — Preventing Celiac Disease by Weaning With Mediterranean Diet · Phase 3 · not yet recruiting
- NCT06073535 — The Use of Injectable-Platelet Rich Fibrin (i-PRF) in the Lower Third Molar Extraction · NA · unknown
- NCT06173492 — Platelet Rich Fibrin (PRF) in Socket Preservation Technique · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06355765 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Naples
- Last refreshed: 17 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06355765.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing